| Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
|
Experimental Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study |
|
European Journal of Haematology |
Aplastic Anemia |
| Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
| Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
|
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
| Detectable mutations precede late myeloid neoplasia in aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates |
|
Semin Hematol |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
